These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

7263 related items for PubMed ID: 11009083

  • 1. Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen.
    Prévost-Blondel A, Neuenhahn M, Rawiel M, Pircher H.
    Eur J Immunol; 2000 Sep; 30(9):2507-15. PubMed ID: 11009083
    [Abstract] [Full Text] [Related]

  • 2. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
    Winter H, Hu HM, Urba WJ, Fox BA.
    J Immunol; 1999 Oct 15; 163(8):4462-72. PubMed ID: 10510388
    [Abstract] [Full Text] [Related]

  • 3. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
    Prévost-Blondel A, Zimmermann C, Stemmer C, Kulmburg P, Rosenthal FM, Pircher H.
    J Immunol; 1998 Sep 01; 161(5):2187-94. PubMed ID: 9725210
    [Abstract] [Full Text] [Related]

  • 4. Virus clearance and immunopathology by CD8(+) T cells during infection with respiratory syncytial virus are mediated by IFN-gamma.
    Ostler T, Davidson W, Ehl S.
    Eur J Immunol; 2002 Aug 01; 32(8):2117-23. PubMed ID: 12209623
    [Abstract] [Full Text] [Related]

  • 5. Compromised virus control and augmented perforin-mediated immunopathology in IFN-gamma-deficient mice infected with lymphocytic choriomeningitis virus.
    Nansen A, Jensen T, Christensen JP, Andreasen SO, Röpke C, Marker O, Thomsen AR.
    J Immunol; 1999 Dec 01; 163(11):6114-22. PubMed ID: 10570301
    [Abstract] [Full Text] [Related]

  • 6. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z, Shatry A, Deyev V, Podack E, Mammolenti M, Blazar BR, Yagita H, Levy RB.
    Biol Blood Marrow Transplant; 2005 Aug 01; 11(8):576-86. PubMed ID: 16041307
    [Abstract] [Full Text] [Related]

  • 7. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus.
    Kreuwel HT, Morgan DJ, Krahl T, Ko A, Sarvetnick N, Sherman LA.
    J Immunol; 1999 Oct 15; 163(8):4335-41. PubMed ID: 10510373
    [Abstract] [Full Text] [Related]

  • 8. The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens.
    Litton MJ, Dohlsten M, Rosendahl A, Ohlsson L, Søgaard M, Andersson J, Andersson U.
    Br J Cancer; 1999 Sep 15; 81(2):359-66. PubMed ID: 10496366
    [Abstract] [Full Text] [Related]

  • 9. Antigen-induced cell death of T effector cells in vitro proceeds via the Fas pathway, requires endogenous interferon-gamma and is independent of perforin and granzymes.
    Sobek V, Balkow S, Körner H, Simon MM.
    Eur J Immunol; 2002 Sep 15; 32(9):2490-9. PubMed ID: 12207333
    [Abstract] [Full Text] [Related]

  • 10. CD8+ T cells mediate aortic allograft vasculopathy by direct killing and an interferon-gamma-dependent indirect pathway.
    Skaro AI, Liwski RS, Zhou J, Vessie EL, Lee TD, Hirsch GM.
    Cardiovasc Res; 2005 Jan 01; 65(1):283-91. PubMed ID: 15621057
    [Abstract] [Full Text] [Related]

  • 11. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR.
    Eur J Immunol; 2009 Oct 01; 39(10):2725-36. PubMed ID: 19637230
    [Abstract] [Full Text] [Related]

  • 12. Rapid on/off cycling of cytokine production by virus-specific CD8+ T cells.
    Slifka MK, Rodriguez F, Whitton JL.
    Nature; 1999 Sep 02; 401(6748):76-9. PubMed ID: 10485708
    [Abstract] [Full Text] [Related]

  • 13. Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens.
    Rosendahl A, Kristensson K, Hansson J, Riesbeck K, Kalland T, Dohlsten M.
    J Immunol; 1998 Jun 01; 160(11):5309-13. PubMed ID: 9605129
    [Abstract] [Full Text] [Related]

  • 14. Perforin-deficient CD8+ T cells: in vivo priming and antigen-specific immunity against Listeria monocytogenes.
    White DW, MacNeil A, Busch DH, Pilip IM, Pamer EG, Harty JT.
    J Immunol; 1999 Jan 15; 162(2):980-8. PubMed ID: 9916723
    [Abstract] [Full Text] [Related]

  • 15. Perforin-dependent cytotoxic activity and lymphokine secretion by CD4+ T cells are regulated by CD8+ T cells.
    Williams NS, Engelhard VH.
    J Immunol; 1997 Sep 01; 159(5):2091-9. PubMed ID: 9278294
    [Abstract] [Full Text] [Related]

  • 16. Immunopotentiating role of IFN-gamma in early and late stages of type 1 CD8 effector cell-mediated tumor rejection.
    Dobrzanski MJ, Reome JB, Dutton RW.
    Clin Immunol; 2001 Jan 01; 98(1):70-84. PubMed ID: 11141329
    [Abstract] [Full Text] [Related]

  • 17. Control of effector CD8+ T cell function by the transcription factor Eomesodermin.
    Pearce EL, Mullen AC, Martins GA, Krawczyk CM, Hutchins AS, Zediak VP, Banica M, DiCioccio CB, Gross DA, Mao CA, Shen H, Cereb N, Yang SY, Lindsten T, Rossant J, Hunter CA, Reiner SL.
    Science; 2003 Nov 07; 302(5647):1041-3. PubMed ID: 14605368
    [Abstract] [Full Text] [Related]

  • 18. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z, Tang C, Xu S, Zhang B, Zhang X, Moyana T, Yang J, Xiang J.
    Cell Mol Immunol; 2007 Aug 07; 4(4):277-85. PubMed ID: 17764618
    [Abstract] [Full Text] [Related]

  • 19. CD8+ T cell-mediated protection against an intracellular bacterium by perforin-dependent cytotoxicity.
    Kägi D, Ledermann B, Bürki K, Hengartner H, Zinkernagel RM.
    Eur J Immunol; 1994 Dec 07; 24(12):3068-72. PubMed ID: 7805735
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 364.